(CercleFinance.com) – TME Pharma announces that the Safety Data Monitoring Board (DSMB) has recommended the continued recruitment of the remaining five patients in accordance with the protocol of its GLORIA phase 1/2 clinical study in glioblastoma.
The DSMB has validated the safety data from the first four weeks of treatment of the first patient enrolled in the expansion arm of this trial with NOX A12 combined with radiotherapy and the PD-1 immune checkpoint inhibitor pembrolizumab .
The biotech company said it reported promising initial data from the bevacizumab expansion arm on June 23, and plans to release more detailed data from the study at a scientific conference later this year.